Likes Subject
pincher chart on the daily and weekly, I
DavidTrader 03/27/23 1:14 PM
Hmmm just crickets around here, I don’t mind Lilman72003 03/22/23 4:17 PM
NKTR -24%/AH on_termination_of Bempeg program following phase-3 failures DewDiligence 04/14/22 5:23 PM
Ouch Ouch Frankestin 03/14/22 10:36 AM
NKTR’s Bempeg fails as addend to Opdivo in DewDiligence 03/14/22 9:57 AM
NKTR +18% on clinical-trial_collaboration_testing Bempeg+Keytruda in_H&N_cancer: DewDiligence 02/17/21 10:21 AM
* * $NKTR Video Chart 01-15-2020 * * ClayTrader 01/15/20 4:41 PM
Comments on the JPM webcast: #msg-153299506. DewDiligence 01/14/20 7:45 PM
We talk about NKTR a little on #board-1418. DewDiligence 01/11/20 2:02 PM
On what board are people discussing Nektar ? Sluicebox 01/11/20 7:21 AM
Yea, bloody taa for !? I will check back. czni 12/14/19 5:36 PM
Well if that wasn’t the strangest thing on czni 12/14/19 5:27 PM
I have been doing a lot of studying czni 12/14/19 5:11 PM
You saw that, yes. thanks but I do not czni 12/14/19 5:04 PM
That’s why I love this board. You don’t czni 12/14/19 5:01 PM
Hey gang, Im a quiet holder but have a czni 12/14/19 4:53 PM
Thinking people are just taking profits today? Clemdane 12/11/19 11:44 AM
News: $NKTR 2 Stocks That Soared Monday While whytestocks 12/09/19 10:45 PM
News: $NKTR Why Nektar Therapeutics Stock Popped Today whytestocks 12/09/19 7:15 PM
News: $NKTR Nektar Therapeutics Announces Presentation of New whytestocks 12/09/19 6:30 PM
News: $NKTR Nektar Therapeutics Presents Data from First-in-Human whytestocks 11/10/19 11:15 AM
News: $NKTR Nektar Therapeutics Presents New Clinical and whytestocks 11/09/19 6:04 PM
* * $NKTR Video Chart 10-08-2019 * * ClayTrader 10/08/19 6:05 PM
Everything You Need For Your Premarket Including Nektar behindthebid 08/09/19 8:58 AM
NKTR says two production lots of NKTR-214 were DewDiligence 08/08/19 5:20 PM
Hmm… DewDiligence 08/08/19 4:25 PM
A trial in Germany is testing a neoantigen jondoeuk 08/06/19 4:54 PM
News: $NKTR Nektar Therapeutics and Bristol-Myers Squibb Announce whytestocks 08/01/19 4:50 PM
NKTR 4Q18 CC transcript: DewDiligence 03/01/19 9:42 AM
ASCO-SITC Clinical Immuno-Oncology Symposium abstract jondoeuk 02/25/19 5:35 PM
Dr. Zalevsky will provide updates on NKTR-214 during jondoeuk 12/29/18 3:43 PM
From this: ''With NKTR-214, a kinetically engineered IL-2 jondoeuk 11/25/18 3:58 PM
SITC data—Melanoma PIVOT-02 ORR=53%* (20*/38)—24% (9/38) CRs: DewDiligence 11/09/18 6:46 PM
I had a few too many. What I jondoeuk 11/08/18 12:30 PM
NKTR 3Q18 results—cash=$2.0B: DewDiligence 11/07/18 6:45 PM
NKTR 3Q18 results—cash=$353M: DewDiligence 11/07/18 4:41 PM
NKTR, PFE ink clinical-trial collaboration for NKTR-214 with DewDiligence 11/06/18 9:29 AM
You own ONCS because of management? DewDiligence 11/03/18 6:42 PM
$GNCA*, $ONCS*, $GRTS, $REPL, $DVAX, $ADRO** and $IDRA*** jondoeuk 11/03/18 6:25 PM
Which biotech companies are you long? TIA DewDiligence 10/27/18 6:40 PM
Melanoma Bridge Conference: 'Immune monitoring after NKTR-214 plus jondoeuk 10/27/18 6:14 PM
Appears that institutions have made up their mind tigerpac 10/24/18 11:47 AM
On second thought, #msg-144383492 is a better explanation DewDiligence 10/22/18 4:01 PM
My take, FWIW: #msg-144374334. DewDiligence 10/22/18 11:24 AM
The shareholder is always the last one to tigerpac 10/22/18 11:16 AM
After examining the "rebuttal" text more closely, I'm DewDiligence 10/04/18 8:30 PM
If that's a real email response from the DewDiligence 10/04/18 3:09 PM
Someone emailed the IR department and posted the jondoeuk 10/04/18 10:34 AM
3 different posters on the NKTR YMB "Conversations" stockbettor 10/04/18 9:22 AM
Where is that from? DewDiligence 10/03/18 6:58 PM
Likes Subject

03/27/23 1:14 PM
03/22/23 4:17 PM
03/14/22 10:36 AM
03/14/22 9:57 AM
01/15/20 4:41 PM
01/14/20 7:45 PM
01/11/20 2:02 PM
12/14/19 5:11 PM
12/09/19 10:45 PM
10/08/19 6:05 PM
08/08/19 5:20 PM
08/06/19 4:54 PM
03/01/19 9:42 AM
11/08/18 12:30 PM
11/07/18 6:45 PM
11/07/18 4:41 PM
11/03/18 6:42 PM
10/27/18 6:40 PM
10/22/18 11:24 AM
10/22/18 11:16 AM
10/04/18 3:09 PM
10/03/18 6:58 PM

Nektar Therapeutics (NKTR)

Posts (Today)
Posts (Total)

Nektar Therapeutics, a biopharmaceutical company, develops various drug products and product candidates using its proprietary drug delivery technologies. Its technology platforms comprise PEGylation Technology designed to enhance the performance of various drug classes, including macromolecules, small molecules, and other drugs; and Pulmonary Technology, which includes technologies for drug formulation, powder processing, powder filling, and packaging, as well as dry powder inhaler devices and liquid nebulizer devices. The company's technologies are used in 10 approved products; 3 partner programs that have been filed for with the FDA; and 12 development programs in human clinical trials. Its partnered products include Tobramycin inhalation powder, a Phase III clinical product for treating lung infections; NKTR-061, a Phase II clinical product for gram-negative pneumonias; Ciprofloxacin Inhalation Powder, a Phase II clinical product for lung infections; Pulmonary dronabinol, a Phase II product for migraine; and Exubera Inhalation Powder for adult type 1 and type 2 diabetes. The company's partnered product portfolio also comprises Neulasta for neutropenia; PEGASY for Hepatitis-C; Somavert for Acromegaly; PEG-INTRON for Hepatitis-C; Macugen for age-related macular degeneration; CIMZIA for Crohn's disease; MIRCERA for renal anemia and chronic kidney disease; CIMZIA for rheumatoid arthritis; Hematide, a Phase III product for Anemia; Macugen, a Phase II clinical trial product for diabetic macular edema and retinal vein occlusion; and CDP 791, a Phase II product for nonsmall cell lung cancer. In addition, Nektar's proprietary products include NKTR-102, a Phase II trial product for colorectal cancer; and NKTR-118, which is in Phase II clinical trials for opioid-induced constipation and other manifestations of opioid bowel dysfunction. The company was founded in 1990 and is headquartered in San Carlos, California.

Most Liked Posts
(Last 30 Days)
New Post